<DOC>
	<DOCNO>NCT02251821</DOCNO>
	<brief_summary>This phase II trial study well give JAK inhibitor donor stem cell transplant work treat patient myelofibrosis develop without another condition ( primary ) evolve bone marrow disorder ( secondary ) . JAK inhibitor class drug may stop growth abnormal cell block enzyme need cell growth . Giving JAK inhibitor donor stem cell transplant may help reduce symptom myelofibrosis inflammation enlargement spleen , improve patient 's general physical condition , prevent complication occur transplant . Infusing healthy stem cell donor patient may help patient 's bone marrow work normally make stem cell , red blood cell , white blood cell , platelet . Giving JAK inhibitor donor stem cell transplant may help improve transplant outcome patient myelofibrosis .</brief_summary>
	<brief_title>JAK Inhibitor Before Donor Stem Cell Transplant Treating Patients With Primary Secondary Myelofibrosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To optimize role allogeneic transplantation primary secondary myelofibrosis ( MF ) JAK inhibitor era . OUTLINE : PART 1 : Patients receive JAK inhibitor ( ruxolitinib , momelotinib , pacritinib ) orally ( PO ) twice daily ( BID ) least 8 week prior start condition best response day -4 transplantation , taper schedule reduce dose every 2-3 day begin day -4 . PART 2 : Patients assign 1 2 conditioning regimen discretion clinical provider Clinical Coordinators Office ( CCO ) . MYELOABLATIVE CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -8 -6 ( umbilical cord blood transplant recipient ) , cyclophosphamide IV day -7 -6 , busulfan IV 3 hour day -5 -2 . REDUCED-INTENSITY CONDITIONING : Patients receive fludarabine phosphate IV 1 hour day -6 -2 melphalan IV 15-30 minute day -3 -2 . Patients also undergo total-body irradiation ( TBI ) day -1 ( umbilical cord blood transplant recipient ) . TRANSPLANT : Patients undergo allogeneic hematopoietic stem cell transplant umbilical cord blood transplant day 0 . GRAFT-VERSUS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients receive tacrolimus IV continuously ( inpatient ) 1-2 hour twice daily ( BID ) ( outpatient ) orally ( PO ) BID day -1 +180 ( patient receive related unrelated stem cell ) day -3 +180 ( patient receive umbilical cord blood ) taper begin day +56 ( relate donor recipient ) +100 ( unrelated donor umbilical cord blood recipient ) absence GVHD . Patients also receive methotrexate IV day +1 , +3 , +6 , +11 ( relate unrelated donor recipient ) mycophenolate mofetil IV PO every 8 hour day 0 +40 taper day +96 ( umbilical cord blood transplant recipient ) . After completion study treatment , patient follow 6 month , 1 2 year , periodically 3 year .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>PART 1 : Disease criterion Diagnosis primary MF ( PMF ) define 2008 World Health Organization classification system diagnosis secondary MF define International Working Group ( IWG ) Myeloproliferative Neoplasms Research Treatment criteria Patients meet criterion intermediate1 , intermediate2 highrisk disease Dynamic International Prognostic Scoring System ( DIPSS ) DIPSSplus score system PART 1 : Ability understand willingness sign write informed consent document PART 2 : Meeting criterion 1st phase , time initiation JAK inhibitor , include ability understand willingness sign write informed consent ; patient arrive institution transplant enrol Part 1 may still enrol Part 2 Part 1 criterion meet ; patient Part 1 endpoint transcribe medical record PART 2 : Received JAK inhibitor least 8 week immediately prior condition able continue Day 4 pretransplant PART 2 : Performance status score Karnofsky &gt; = 70 PART 2 : Calculated creatinine clearance use CockcroftGault formula 24 hr urine creatinine clearance must &gt; 60 ml/min PART 2 : Total serum bilirubin must &lt; 3 mg/dL unless elevation thought due Gilbert 's disease hemolysis PART 2 : Transaminases must &lt; 3 x upper limit normal PART 2 : Patients clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient fulminant liver failure , cirrhosis evidence portal hypertension bridge fibrosis , alcoholic hepatitis , hepatic encephalopathy , correctable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease exclude PART 2 : Diffusing capacity lung carbon monoxide ( DLCO ) correct &gt; 60 % normal May supplemental oxygen PART 2 : Left ventricular ejection fraction &gt; 40 % OR PART 2 : Shortening fraction &gt; 26 % PART 2 : Comorbidity Index &lt; 5 time pretransplant evaluation DONOR : Human leukocyte antigen ( HLA ) match 1 antigen mismatch sibling donor DONOR : 10 10 HLAmatched 1 allele mismatch ( 9 10 ) unrelated donor DONOR : Peripheral blood prefer bone marrow nonumbilical cord blood recipient DONOR : Umbilical cord blood unit select accord follow umbilical cord blood graft selection criterion ; one 2 cord blood ( CB ) unit may use achieve require cell dose DONOR : The CB graft ( ) must match 46 HLAA , B , DR Beta 1 ( DRB1 ) locus recipient therefore may include 02 mismatch A B DRB1 locus ; unit selection base cryopreserved nucleated cell dose intermediate resolution A , B antigen DRB1 allele type determination HLAmatch ; HLAC antigen/allele level typing consider matching criterion , available , may use optimize unit selection DONOR : Selection two CB unit allow provide sufficient cell dose ( see algorithm determine single versus double unit transplant ) ; multiple unit select , follow rule apply : The CB unit least HLA disparity ( patient ) select first ( i.e. , selection priority 6/6 match &gt; 5/6 match &gt; 4/6 match ) ; additional CB unit may select achieve require cell dose , outline ; second unit require , unit unit closely HLA match patient meet minimum size criterion outline least 1.5 x 10^7 total nucleated cell ( TNC ) /kg ( i.e . small , closely matched unit select large , less well matched unit long minimum criterion meet ) If two CB unit use : The total cell dose combine unit must least 3.0 x 10^7 TNC per kilogram recipient weight Each CB unit MUST contain least 1.5 x 10^7 TNC per kilogram recipient weight Algorithm determine single versus double unit cord blood transplant : Match grade 6/6 : TNC dose &gt; = 2.5 x 10^7/kg Match grade 5/6 , 4/6 : TNC dose &gt; = 4.0 ( +/ 0.5 ) x 10^7/kg DONOR : General comment : Units select first base TNC dose HLA match Cluster differentiation ( CD ) 34+ cell dose use unit selection unless 2 unit equal HLAmatch grade similar TNC dose ( +/ 0.5 x 10^7 TNC/kg ) available ; case , unit large CD34+ cell dose ( data available ) select A CB unit 5/6 mismatch homozygous locus mismatch choose 5/6 unit bidirectional mismatch even latter unit large ( cell ) ; also apply 4/6 unit ; applicable choose unit within give match grade Other factor consider : Within HLA match grade , match DR take preference Cord blood bank locate United States prefer Up 5 % cord blood product ( ) , ready infusion , may withhold research purpose long threshold infuse TNC dose meet ; product use conduct study involve kinetics engraftment immunobiology double cord transplantation PART 1 : Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology PART 1 : Uncontrolled viral , bacterial , fungal infection time study enrollment PART 1 : History prior allogeneic transplant PART 1 : Pregnant breastfeed PART 2 : Uncontrolled viral bacterial infection time study enrollment PART 2 : Active recent ( prior 6 month ) invasive fungal infection without infectious disease ( ID ) consult approval PART 2 : History HIV infection PART 2 : Pregnant breastfeed PART 2 : Patients without HLAidentical 1allelemismatched relate donor unrelated donor umbilical cord blood unit meet transplant criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>